


We Claim:

1. A compound of formula (IA-I)



(IA-I)

or a tautomer, stereoisomer, enantiomer, diastereomer, a prodrug, a pharmaceutically acceptable salt, or N-oxide thereof; wherein

X is CR¹ or N;

D is substituted or unsubstituted monocyclic aryl or substituted or unsubstituted monocyclic heteroaryl; wherein D is substituted with a group E which is selected from -CONH-O-(CR^xR^y)_p-OR^x, -CONH-(CR^xR^y)_p-OR^x, -CONH-(CR^xR^y)_p-NR^xR^y, -CONH-(CR^xR^y)_p-S(O)_qR^x, -CONH-O-(CR^xR^y)_p-[cycloalkyl]-(CR^xR^y)_p-OR^x, -CONH-(CR^xR^y)_p-[cycloalkyl]-(CR^xR^y)_p-OR^x, -CONH-(CR^xR^y)_p-[cycloalkyl]-(CR^xR^y)_p-NR^xR^y, and -CONH-(CR^xR^y)_p-[cycloalkyl]-(CR^xR^y)_p-S(O)_qR^x; and further D can optionally be substituted with one or more of R^z;

L₂ is selected from -O-, -S(=O)_q-, -NR^a-, -(CR^aR^b)_n-, -C(=Y)-, -C(=Y)-C(=Y)-, -CR^aR^b-C(=Y)-CR^aR^b-, -CR^aR^b-Y-CR^aR^b-, -C(=Y)-NR^a-, -NR^a-C(=Y)-NR^a-, -S(=O)_q-NR^a-, -NR^a-S(=O)_q-NR^a-, -NR^a-NR^a-, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocyclyl;

Cy² is independently selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

each occurrence of R¹ and R² may be same or different and is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, -OR^a, -S(=O)_q-R^a, -NR^aR^b, -C(=Y)-R^a, -

$\text{CR}^a\text{R}^b\text{-C(=Y)-R}^a$, $\text{-CR}^a\text{R}^b\text{-Y-CR}^a\text{R}^b$, $\text{-C(=Y)-NR}^a\text{R}^b$, $\text{-NR}^a\text{R}^b\text{-C(=Y)-NR}^a\text{R}^b$, $\text{-S(=O)}_q\text{-NR}^a\text{R}^b$, $\text{-NR}^a\text{R}^b\text{-S(=O)}_q\text{-NR}^a\text{R}^b$, $\text{-NR}^a\text{R}^b\text{-NR}^a\text{R}^b$, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} cycloalkyl, substituted or unsubstituted C_{3-6} cycloalkylalkyl, and substituted or unsubstituted C_{3-6} cycloalkenyl;

each occurrence of Y is independently selected from O, S, and NR^a ;

each occurrence of R^a and R^b may be same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} cycloalkyl, substituted or unsubstituted C_{3-6} cycloalkylalkyl, and substituted or unsubstituted C_{3-6} cycloalkenyl, or when two R^a and/or R^b substituents are directly bound to a common atom, they may be joined to form a substituted or unsubstituted, saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR^c or S;

each occurrence of R^c is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} cycloalkyl, substituted or unsubstituted C_{3-6} cycloalkylalkyl, and substituted or unsubstituted C_{3-6} cycloalkenyl;

each occurrence of R^x and R^y is independently selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo ($=\text{O}$), thio ($=\text{S}$), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocycyl, substituted or unsubstituted heterocycylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, $-\text{COOR}^z$, $-\text{C(O)R}^z$, $-\text{C(S)R}^z$, $-\text{C(O)NR}^z\text{R}^z$, $-\text{C(O)ONR}^z\text{R}^z$, $-\text{NR}^z\text{R}^z$, $-\text{NR}^z\text{CONR}^z\text{R}^z$, $-\text{N(R}^z\text{)SOR}^z$, $-\text{N(R}^z\text{)SO}_2\text{R}^z$, $-(=\text{N-N(R}^z\text{)R}^z)$, $-\text{NR}^z\text{C(O)OR}^z$, $-\text{NR}^z\text{C(O)R}^z$, $-\text{NR}^x\text{C(S)R}^y$, $-\text{NR}^z\text{C(S)NR}^z\text{R}^z$, $-\text{SONR}^z\text{R}^z$, $-\text{SO}_2\text{NR}^z\text{R}^z$, $-\text{OR}^z$, $-\text{OR}^z\text{C(O)NR}^z\text{R}^z$, $-\text{OR}^z\text{C(O)OR}^z$, $-\text{OC(O)R}^z$, $-\text{OC(O)NR}^z\text{R}^z$, $-\text{R}^z\text{NR}^z\text{C(O)R}^z$, $-\text{R}^z\text{OR}^z$, $-\text{R}^z\text{C(O)OR}^z$, $-\text{R}^z\text{C(O)NR}^z\text{R}^z$, $-\text{R}^z\text{C(O)R}^z$, $-\text{R}^z\text{OC(O)R}^z$, $-\text{SR}^z$, $-\text{SOR}^z$,

$-\text{SO}_2\text{R}^z$, and $-\text{ONO}_2$, or any two of R^x and R^y which are directly bound to a common atom may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR^z or S, or (ii) an oxo ($=\text{O}$), thio ($=\text{S}$) or imino ($=\text{NR}^z$); wherein


each occurrence of R^z is independently hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo ($=\text{O}$), thio ($=\text{S}$), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocycyl, substituted or unsubstituted heterocyclyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, and $-\text{ONO}_2$, or any two of R^z which are directly bound to a common atom may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR^z (where R^z is H or alkyl) or S, or (ii) an oxo ($=\text{O}$), thio ($=\text{S}$) or imino ($=\text{NR}^z$);

each occurrence of n independently represents 0, 1, 2, 3 or 4;

each occurrence of p independently represents 0, 1-7 or 8; and

each occurrence of q independently represents 0, 1 or 2.

2. A compound of claim 1, wherein




E is selected from $-\text{CONH}-\text{O}-(\text{CR}^x\text{R}^y)_p-\text{OR}^x$, $-\text{CONH}-(\text{CR}^x\text{R}^y)_p-\text{OR}^x$, $-\text{CONH}-(\text{CR}^x\text{R}^y)_p-\text{NR}^x\text{R}^y$, $-\text{CONH}-(\text{CR}^x\text{R}^y)_p-\text{S}(\text{O})_q\text{R}^x$, $-\text{CONH}-\text{O}-(\text{CR}^x\text{R}^y)_p-[\text{cycloalkyl}]-(\text{CR}^x\text{R}^y)_p-\text{OR}^x$, $-\text{CONH}-(\text{CR}^x\text{R}^y)_p-[\text{cycloalkyl}]-(\text{CR}^x\text{R}^y)_p-\text{OR}^x$, $-\text{CONH}-(\text{CR}^x\text{R}^y)_p-[\text{cycloalkyl}]-(\text{CR}^x\text{R}^y)_p-\text{NR}^x\text{R}^y$, and $-\text{CONH}-(\text{CR}^x\text{R}^y)_p-[\text{cycloalkyl}]-(\text{CR}^x\text{R}^y)_p-\text{S}(\text{O})_q\text{R}^x$; and


X^1 , X^2 and X^3 are independently selected from $-\text{CR}^z$, $-\text{CR}^z=\text{CR}^z$, $-\text{CR}^z=\text{N}$, $-\text{N}=\text{CR}^z$, $-\text{N}=\text{N}-$, $\text{O}-$, $-\text{S}-$ or $-\text{N}-$.

3. A compound of any one of claims 1 and 2, wherein Cy^2 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

4. A compound of any one of claims 1-3, wherein Cy^2 is selected from




5. A compound of any one of claims 3 and 4, wherein Cy^2 is selected from



6. A compound of any one of claims 1-5, wherein L_2 is $-\text{CR}^a\text{R}^b-$.


7. A compound of claim 6, wherein L_2 is $-\text{CH}_2-$, $-\text{CH}(\text{OH})-$, $-\text{CHF}-$, $-\text{CF}_2-$, $-\text{CH}(\text{CH}_3)-$ or $-\text{C}(\text{CH}_3)_2-$.

8. A compound of any one of claims 1-7, wherein L_2 is $-\text{CH}_2$.
9. A compound of formula (IA-I):



(IA-I)

or a tautomer, stereoisomer, enantiomer, diastereomer, a prodrug, a pharmaceutically acceptable salt, or N-oxide thereof, wherein



$-\text{L}_2\text{-Cy}^2$ is

(where the squiggly line represents the bond to the bicyclic core in formula (IA-I);

(where the squiggly line represents the

each occurrence of R^a and R^b are independently selected from hydrogen, halogen, and substituted or unsubstituted (C_{1-6}) alkyl, or both together with the carbon atom to which they are attached form a saturated 3 to 6 member cyclic ring which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR^e and S (where R^e is R^z);

Z is selected from CR^e , S, O, NR^e , $\text{R}^e\text{C}=\text{CR}^e$, $-\text{N}=\text{CR}^e$, and $-\text{R}^e\text{C}=\text{N}-$;

Z_1 is selected from N, NR^e and CR^e ;

Z_2 and Z_3 are independently selected from C or N;

R^e is absent or selected from hydrogen, hydroxy and halogen;

X is CR^1 or N;

D is substituted or unsubstituted monocyclic aryl or substituted or unsubstituted monocyclic heteroaryl; wherein D is substituted with a group E which is selected from -CONH-O-(CR^xR^y)_p-OR^x, -CONH-(CR^xR^y)_p-OR^x, -CONH-(CR^xR^y)_p-NR^xR^y, -CONH-(CR^xR^y)_p-S(O)_qR^x, -CONH-O-(CR^xR^y)_p-[cycloalkyl]-(CR^xR^y)_p-OR^x, -CONH-(CR^xR^y)_p-[cycloalkyl]-(CR^xR^y)_p-OR^x, -CONH-(CR^xR^y)_p-[cycloalkyl]-(CR^xR^y)_p-NR^xR^y, and -CONH-(CR^xR^y)_p-[cycloalkyl]-(CR^xR^y)_p-S(O)_qR^x; and further D can optionally be substituted with one or more of R^z;

each occurrence of R¹ and R² may be same or different and is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, -OR^a, -S(=O)_q-R^a, -NR^aR^b, -C(=Y)-R^a, -CR^aR^b-C(=Y)-R^a, -CR^aR^b-Y-CR^aR^b, -C(=Y)-NR^aR^b, -NR^aR^b-C(=Y)-NR^aR^b, -S(=O)_q-NR^aR^b, -NR^aR^b-S(=O)_q-NR^aR^b, -NR^aR^b-NR^aR^b, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted C₃₋₆ cycloalkyl, substituted or unsubstituted C₃₋₆ cycloalkylalkyl, and substituted or unsubstituted C₃₋₆ cycloalkenyl;

each occurrence of Y is independently selected from O, S, and NR^a;


each occurrence of R^x and R^y is independently selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (=O), thio (=S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocycyl, substituted or unsubstituted heterocycylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, -COOR^z, -C(O)R^z, -C(S)R^z, -C(O)NR^zR^z, -C(O)ONR^zR^z, -NR^zR^z, -NR^zCONR^zR^z, -N(R^z)SOR^z, -N(R^z)SO₂R^z, -(=N-N(R^z)R^z), -NR^zC(O)OR^z, -NR^zC(O)R^z, -NR^xC(S)R^y-NR^zC(S)NR^zR^z, -SONR^zR^z, -SO₂NR^zR^z, -OR^z, -OR^zC(O)NR^zR^z, -OR^zC(O)OR^z, -OC(O)R^z, -OC(O)NR^zR^z, -R^zNR^zC(O)R^z, -R^zOR^z, -R^zC(O)OR^z, -R^zC(O)NR^zR^z, -R^zC(O)R^z, -R^zOC(O)R^z, -SR^z, -SOR^z, -SO₂R^z, and -ONO₂, or any two of R^x and R^y which are directly bound to a common atom may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR^z or S, or (ii) an oxo (=O), thio (=S) or imino (=NR^z), wherein

each occurrence of R^z is independently hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo ($=O$), thio ($=S$), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocycyl, substituted or unsubstituted heterocyclyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, and $-ONO_2$, or any two of R^z which are directly bound to a common atom may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR' (where R' is H or alkyl) or S, or (ii) an oxo ($=O$), thio ($=S$) or imino ($=NR''$);

each occurrence of q independently represents 0, 1 or 2; and


each occurrence of p independently represents 0, 1-7 or 8.


10. A compound of formula (IA-I):



(IA-I)

or a tautomer, stereoisomer, enantiomer, diastereomer, a prodrug, a pharmaceutically acceptable salt, or N-oxide thereof, wherein





L_2-Cy^2 is (where the squiggly line represents the bond to the bicyclic core in formula (IA-I);

X is CR^1 or N;

X^1 , X^2 and X^3 are independently selected from $-CR^z$, $-CR^z=CR^z$, $-CR^z=N$, $-N=CR^z$, $-N=N-$, O-, -S- or -N-;

Z is selected from CR^c , S, O, NR^c , $R^cC=CR^c$, $-N=CR^c$, and $-R^cC=N-$;

Z_1 is selected from N, NR^c and CR^c ;

Z_2 and Z_3 are independently selected from C or N;

E is $-CONH-O-(CR^xR^y)_p-OR^x$, $-CONH-(CR^xR^y)_p-OR^x$, $-CONH-(CR^xR^y)_p-NR^xR^y$, $-CONH-(CR^xR^y)_p-S(O)_qR^x$, $-CONH-O-(CR^xR^y)_p-[cycloalkyl]-(CR^xR^y)_p-OR^x$, $-CONH-(CR^xR^y)_p-[cycloalkyl]-(CR^xR^y)_p-OR^x$, $-CONH-(CR^xR^y)_p-[cycloalkyl]-(CR^xR^y)_p-NR^xR^y$, or $-CONH-(CR^xR^y)_p-[cycloalkyl]-(CR^xR^y)_p-S(O)_qR^x$

each occurrence of R^1 and R^2 may be same or different and is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, $-OR^a$, $-S(=O)_qR^a$, $-NR^aR^b$, $-C(=Y)-R^a$, $-CR^aR^b-C(=Y)-R^a$, $-CR^aR^b-Y-CR^aR^bR^b$, $-C(=Y)-NR^aR^b$, $-NR^aR^b-C(=Y)-NR^aR^b$, $-S(=O)_q-NR^aR^b$, $-NR^aR^b-S(=O)_q-NR^aR^b$, $-NR^aR^b-NR^aR^b$, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} cycloalkyl, substituted or unsubstituted C_{3-6} cycloalkylalkyl, and substituted or unsubstituted C_{3-6} cycloalkenyl;

each occurrence of Y is independently selected from O, S, and NR^a ;

each occurrence of R^a and R^b may be same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} cycloalkyl, substituted or unsubstituted C_{3-6} cycloalkylalkyl,

and substituted or unsubstituted C₃₋₆ cycloalkenyl, or when two R^a and/or R^b substituents are directly bound to a common atom, they may be joined to form a substituted or unsubstituted, saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR^c or S, preferably each occurrence of R^a and R^b are independently selected from hydrogen, halogen, and substituted or unsubstituted (C₁₋₆) alkyl, or both together with the carbon atom to which they are attached form a saturated 3 to 6 member cyclic ring which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR^e and S (where R^e is R^z);

each occurrence of R^c is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted C₃₋₆ cycloalkyl, substituted or unsubstituted C₃₋₆ cycloalkylalkyl, and substituted or unsubstituted C₃₋₆ cycloalkenyl, preferably R^c is absent or selected from hydrogen, hydroxy and halogen;

each occurrence of R^x and R^y is independently selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (=O), thio (=S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocycyl, substituted or unsubstituted heterocycylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, -COOR^z, -C(O)R^z, -C(S)R^z, -C(O)NR^zR^z, -C(O)ONR^zR^z, -NR^zR^z, -NR^zCONR^zR^z, -N(R^z)SOR^z, -N(R^z)SO₂R^z, -(=N-N(R^z)R^z), -NR^zC(O)OR^z, -NR^zC(O)R^z, -NR^xC(S)R^y-NR^zC(S)NR^zR^z, -SONR^zR^z, -SO₂NR^zR^z, -OR^z, -OR^zC(O)NR^zR^z, -OR^zC(O)OR^z, -OC(O)R^z, -OC(O)NR^zR^z, -R^zNR^zC(O)R^z, -R^zOR^z, -R^zC(O)OR^z, -R^zC(O)NR^zR^z, -R^zC(O)R^z, -R^zOC(O)R^z, -SR^z, -SOR^z, -SO₂R^z, and -ONO₂, or any two of R^x and R^y which are directly bound to a common atom may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR^z or S, or (ii) an oxo (=O), thio (=S) or imino (=NR^z); wherein

each occurrence of R^z is independently hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo ($=O$), thio ($=S$), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocycyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, and $-ONO_2$, or any two of R^z which are directly bound to a common atom may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR' (where R' is H or alkyl) or S, or (ii) an oxo ($=O$), thio ($=S$) or imino ($=NR''$);


each occurrence of q independently represents 0, 1 or 2;


each occurrence of p independently represents 0, 1-7 or 8.


11. A compound of claim 2 or claim 10, wherein X^1 and X^2 are CR^z and X^3 is independently selected from $-CR^z=CR^z$ and $-S-$.


12. A compound of claim 11, wherein X^1 is CH, X^2 is CR^z and X^3 is $-CR^z=CR^z$, wherein R^z is hydrogen, halogen or substituted or unsubstituted C_{1-3} alkyl.


13. A compound of any one of claims 1-12, wherein D is selected from














14. A compound of claim 13, wherein D is selected from







15. A compound of any one of claims 1-12, wherein D is selected from



16. A compound of claim 15 wherein E is selected from



17. A compound of claim 15 or claim 16, wherein E is selected from



18. A compound of claim 15, wherein each occurrence of R^Z is selected from hydrogen, halogen or substituted or unsubstituted alkyl.
19. A compound of claim 18, wherein each occurrence of R^Z is selected from hydrogen, fluoro, chloro, methyl or CF_3 .
20. A compound of claims 9-19, wherein each of R^a and R^b is hydrogen, alkyl or halogen.
21. A compound of any one of claims 9-20, wherein
 - a) both R^a and R^b are hydrogen;
 - b) R^a is methyl and R^b is hydrogen;
 - c) R^a is fluoro and R^b is hydrogen;
 - d) R^a and R^b both are fluoro; or
 - e) R^a and R^b both are methyl.
22. A compound of any one of claims 9-21, wherein

Z is CR^c , N, S, O, $HC=CH-$ or $-N=CH-$;

Z_1 is CH or N;

Z_2 is C; and

Z_3 is C or N.
23. A compound of any one of claims 9-22, wherein
 - a) Z is $-HC=CH-$, $-S-$ or $-O-$; Z_1 is CH; Z_2 is C and Z_3 is C or N;
 - b) Z is $-HC=CH-$, Z_1 is CH; Z_2 is C; and Z_3 is C;

- c) Z is CH, Z₁ is CH, Z₂ is C and Z₃ is N;
- d) Z is -S-, Z₁ is CH, Z₂ is C and Z₃ is C;
- e) Z is -O-, Z₁ is CH, Z₂ is C and Z₃ is C; or
- f) Z is -CH-, Z₁ is NH, Z₂ is C and Z₃ is C.

24. A compound of any one of claims 9-23, wherein each occurrence of R^c is hydrogen or fluoro.

25. A compound of any one of claims 1-24, wherein X is N or CR¹ and R¹ is H, substituted or unsubstituted C₁₋₆ alkyl, NH₂, OH, CN or CONH₂.

26. A compound of any one of claims 1-25, wherein X is N.

27. A compound of any one of claims 1-26, wherein each R² is H.

28. A compound selected from:

N-(2-amino-2-oxoethyl)-4-(3-(quinolin-7-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(2-(methylamino)-2-oxoethyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl) benzamide:

N-(3-amino-3-oxopropyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(3-(methylamino)-3-oxopropyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

2-chloro-N-(2-(pyrrolidin-1-yl)ethyl)-4-(3-(quinolin-7-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl) benzamide hydrochloride:

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 4-methylbenzenesulfonate

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrobromide:

sodium (2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide:

2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride:

sodium (2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2-chloro-4-(3-((7-fluoro-2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride:

sodium (2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide

2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride

sodium (2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2-fluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl acetate:

(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl 2-(tert-butoxycarbonylamino)propanoate:

(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl 2-aminopropanoate:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl pivalate:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl isobutyrate:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl 2-benzamidoacetate:

2-chloro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-chloro-N-(2-hydroxyethoxy)benzamide:

4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2,6-difluoro-N-(2-hydroxyethoxy)benzamide:

sodium (4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2,6-difluorobenzoyl)(2-hydroxyethoxy)amide:

4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-fluoro-N-(2-hydroxyethoxy)benzamide:

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride:

N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-(trifluoromethyl)benzamide:

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide:

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide hydrochloride:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrobromide:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 4-methylbenzenesulfonate:

N-(2-hydroxyethoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

6-((5-(4-(2-hydroxyethoxycarbonyl)-3-methylphenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline 1-oxide

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-methylbenzamide:

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-methylbenzamide hydrochloride:

2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide:

2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride:

2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

ethyl 2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)acetate:

2-chloro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

(S)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

(R)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2,6-difluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2-fluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

(S)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

(R)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

N-(1-hydroxy-2-methylpropan-2-yloxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

2-chloro-N-(1-hydroxy-2-methylpropan-2-yloxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-[3-(1-oxy-quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl]-benzamide

N-Hydroxy-2-methyl-4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-benzamide

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl acetate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl isobutyrate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl pivalate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl benzoate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl furan-2-carboxylate

1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone

2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethylidene)hydrazinecarboxamide hydrochloride

2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethylidene)hydrazinecarbothioamide

6-((5-(1-(2-(pyridin-2-yl)hydrazono)ethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl) quinoline

2-(amino(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)methylene)hydrazinecarboxamide:

tert-butyl 2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethylidene) hydrazinecarboxylate:

(E/Z)-1-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethylideneamino)imidazolidine-2,4-dione:

N-ethyl-2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethylidene) hydrazinecarbothioamide:

2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethylidene) hydrazinecarbothioamide hydrochloride:

2-(1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethylidene) hydrazinecarbothioamide:

Methyl 2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethylidene) hydrazinecarboxylate:

1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone oxime:

1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone O-methyl oxime:

1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone O-2-hydroxyethyl oxime:

1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone O-2-hydroxyethyl oxime:

1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone O-2-aminoethyl oxime:

1-(2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethylideneaminoxy)ethyl)urea:

1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone
O-methyl oxime hydrochloride:

1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone
oxime hydrochloride:

1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone
O-2-hydroxyethyl oxime hydrochloride:

N-(3-Dimethylamino-propyl)-4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-
b]pyridin-5-yl)-benzamide dihydrochloride:

or a pharmaceutically acceptable salts thereof.

29. A compound selected from:

2-chloro-N-(2-(dimethylamino)ethyl)-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-
b]pyridin-5-yl)benzamide:

2-chloro-N-(3-(dimethylamino)propyl)-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]
pyridin-5-yl)benzamide:

2-chloro-N-methoxy-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)
benzamide:

N-(2-(dimethylamino)ethyl)-2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-
b]pyridin-5-yl)benzamide:

2,6-difluoro-N-methoxy-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)
benzamide:

1-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)ethanone:

2-(1-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)ethylidene)
hydrazinecarboxamide:

2-(1-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)ethylidene)
hydrazinecarbothioamide:

(R)-2-fluoro-N-(2-hydroxypropyl)-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamide

(S)-2-fluoro-N-(2-hydroxypropyl)-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamide

N-(2-Hydroxy-ethoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide

N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide

2-Chloro-N-(2-hydroxy-ethoxy)-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide

2-Chloro-N-(2-hydroxy-2-methyl-propoxy)-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide:

or a pharmaceutically acceptable salts thereof

30. A compound selected from:

6-((5-(4-carbamoyl-3,5-difluorophenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline 1-oxide:

6-((5-(4-carbamoyl-3-chlorophenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)-7-fluoroquinoline 1-oxide:

2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 2,2,2-trifluoroacetate:

2-chloro-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2,6-difluoro-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2,6-difluorobenzamide:

2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl) benzamide:

2-Chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamide:

2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamide hydrochloride:

2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamide:

Methyl 2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzoate:

2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzoic acid:

2-chloro-N-ethyl-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamide:

Methyl 2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzoate:

2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzoic acid:

N-ethyl-2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl) benzamide:

2-chloro-N-methyl-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl) benzamide:

2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamide:

2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamide 2,2,2-trifluoroacetate:

2-chloro-4-(2-methyl-3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl) benzamide:

2-chloro-4-(3-(1-(quinolin-6-yl)ethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamide:

2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamide:

2-chloro-4-(3-((5,7-difluoroquinolin-6-yl)methyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamide:

4-(3-Quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-2-trifluoromethylbenzamide

4-[3-(7-Fluoro-quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-methylbenzamide

4-[3-(7-Fluoro-quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-trifluoromethylbenzamide

4-[3-(5,7-Difluoro-quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-methylbenzamide

4-[3-(5,7-Difluoro-quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-trifluoromethylbenzamide

4-[3-(7-Fluoro-quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-methylbenzamide hydrochloride

2,N-Dimethyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide

5-(3-Quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-pyridine-2-carboxylic acid methylamide

5-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2,3-dihydroisoindol-1-one

5-(3-Quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-2,3-dihydro-isoindol-1-one

or a pharmaceutically acceptable salts thereof

31. A pharmaceutical composition comprising a compound of any one of claims 1-30 and a pharmaceutically acceptable carrier.

32. The pharmaceutical composition of claim 31, further comprising one or more additional therapeutic agents and mixtures thereof.


33. The pharmaceutical composition of claim 32, wherein the one or more additional therapeutic agent is an anti-cancer agent, anti-inflammatory agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, antihistamine, analgesic, or a mixture thereof.
34. Use of a compound of any one of claims 1-30 in the manufacture of a medicament for the treatment of a disease, disorder, or condition that would benefit from inhibiting catalytic activity of a kinase.
35. Use of a compound of claim 34, wherein the kinase is c-Met kinase.
36. A method of inhibiting the HGF/c-Met kinase signaling pathway in a cell comprising contacting said cell with a compound of any one of claims 1-30.
37. A method of inhibiting the proliferative activity of a cell comprising contacting said cell with a compound of any one of claims 1-30.
38. A method of inhibiting tumor growth in a patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1-30.
39. A method of inhibiting tumor metastasis in a patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1-30.
40. A method for the treatment of a c-Met associated disease or disorder, comprising the step of administering to a subject in need thereof an effective amount of compound of any one of claims 1-30.
41. The method of claim 40, further comprising the step of administering simultaneously or sequentially to a subject in need thereof at least one other anti-cancer agent, anti-inflammatory agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, antihistamine, analgesic, or a mixture thereof.
42. The method of claim 40 or claim 41, wherein the c-Met associated disease, disorder or condition is an immune system-related disease, a disease or disorder involving inflammation, cancer or other proliferative disease, a hepatic disease or disorder, or a renal disease or disorder.
43. A method of treating a cancer in a patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1-30.

44. The method of claim 43, wherein said cancer is a carcinoma, musculoskeletal sarcoma, soft tissue sarcoma, or hematopoietic malignancy.

45. The method of claim 44, wherein said cancer is carcinoma of the bladder, carcinoma of the breast, carcinoma of the colon, carcinoma of the kidney, carcinoma of the liver, carcinoma of the lung, small cell lung cancer, esophageal cancer, gall bladder cancer, ovarian cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, prostate cancer, skin cancer, squamous cell carcinoma; cholangiocarcinoma cancer, tumors of mesenchymal origin, fibrosarcoma, rhabdomyosarcoma; tumors of the central and peripheral nervous system, astrocytoma, neuroblastoma, glioma, schwannoma, melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderma pigmentosum, keratocanthoma, thyroid follicular cancer and Kaposi's sarcoma, synovial sarcoma, rhabdomyosarcoma, MFH/fibrosarcoma, leiomyosarcoma, multiple myeloma, lymphoma, glioblastoma, astrocytoma, melanoma, mesothelioma, Wilm's tumor, hematopoietic tumors of lymphoid lineage, leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, acute myelogenous leukemias, chronic myelogenous leukemias, myelodysplastic syndrome, or promyelocytic leukemia.

We claim:

1. A compound of formula (IA-I)



(IA-I)

or a tautomer, stereoisomer, enantiomer, diastereomer, a prodrug, a pharmaceutically acceptable salt, or N-oxide thereof; wherein

X is CR¹ or N;

D is monocyclic aryl or monocyclic heteroaryl; wherein D is substituted with a group E which is selected from -CONH-O-(CR^xR^y)_p-OR^x, -CONH-O-[cycloalkyl]-(CR^xR^y)_p-OR^x, and -CONH-O-(CR^xR^y)_p-[cycloalkyl]-OR^x, and further D can optionally be substituted with one or more of R^z;

L₂ is -(CR^aR^b)_n,

Cy² is substituted or unsubstituted heteroaryl;

each occurrence of R¹ and R² hydrogen

each occurrence of R^a and R^b may be same or different and are independently selected from hydrogen, hydroxy, halogen, and substituted or unsubstituted C₁₋₆ alkyl,


each occurrence of R^x and R^y is independently selected from hydrogen, hydroxy, substituted or unsubstituted alkyl, and substituted or unsubstituted alkoxy wherein

each occurrence of R^z is independently hydrogen, halogen, or substituted or unsubstituted alkyl each occurrence of n independently represents 0, 1, 2, 3 or 4;

each occurrence of p independently represents 1, 2, 3, 4, 5, 6, 7 or 8; and

each occurrence of q independently represents 0, 1 or 2.

2. A compound of claim 1, wherein




E is selected from $-\text{CONH-O}-(\text{CR}^x\text{R}^y)_p-\text{OR}^x$, $-\text{CONH-O}[\text{cycloalkyl}](\text{CR}^x\text{R}^y)_p-\text{OR}^x$, and $-\text{CONH-O}-(\text{CR}^x\text{R}^y)_p[\text{cycloalkyl}]-\text{OR}^x$, and


X^1 , X^2 and X^3 are independently selected from $-\text{CR}^z$, $-\text{CR}^z=\text{CR}^z$, $-\text{CR}^z=\text{N}$, $-\text{N}=\text{CR}^z$, $-\text{N}=\text{N}-$, $\text{O}-$, $-\text{S}-$ or $-\text{N}-$.

3. A compound of any one of claims 1 and 2, wherein Cy^2 is unsubstituted heteroaryl.


4. A compound of any one of claims 1-2, wherein Cy^2 is selected from



5. A compound of claim 4, wherein Cy^2 is selected from




6. A compound of any one of claims 1-5, wherein L_2 is $-CR^aR^b-$.
7. A compound of claim 6, wherein L_2 is $-CH_2-$, $-CH(OH)-$, $-CHF-$, $-CF_2-$, $-CH(CH_3)-$ or $-C(CH_3)_2-$.
8. A compound of any one of claims 1-7, wherein L_2 is $-CH_2-[-CH_2-]$.
9. A compound of formula (IA-I):



(IA-I)

or a tautomer, stereoisomer, enantiomer, diastereomer, a prodrug, a pharmaceutically acceptable salt, or N-oxide thereof, wherein



$-L_2-Cy^2$ is

(where the squiggly line represents the

bond to the bicyclic core in formula (IA-I);

each occurrence of R^a and R^b are independently selected from hydrogen, halogen, and substituted or unsubstituted (C_{1-6}) alkyl Z is selected from CR^c , S , O , NR^c , $R^cC=CR^c$, $-N=CR^c$, and $-R^cC=N-$;

Z_1 is selected from N , NR^c and CR^c ;

Z_2 and Z_3 are independently selected from C or N;

R^c is absent or selected from hydrogen, hydroxy and halogen;

X is CR^1 or N;

D is monocyclic aryl or monocyclic heteroaryl; wherein D is substituted with a group E which is selected from $-CONH-O-(CR^xR^y)_p-OR^x$, $-CONH-O-[cycloalkyl]-(CR^xR^y)_p-OR^x$, and $-CONH-O-(CR^xR^y)_p-[cycloalkyl]-OR^x$, and further D can optionally be substituted with one or more of R^z ;

each occurrence of R^1 and R^2 hydrogen


each occurrence of R^x and R^y is independently selected from hydrogen, hydroxy, substituted or unsubstituted alkyl, and substituted or unsubstituted alkoxy;

each occurrence of R^z is independently hydrogen, halogen, or substituted or unsubstituted alkyl

each occurrence of q independently represents 0, 1 or 2; and



each occurrence of p independently represents 1, 2, 3, 4, 5, 6, 7 or 8.

10. A compound of formula (IA-I):



(IA-I)

or a tautomer, stereoisomer, enantiomer, diastereomer, a prodrug, a pharmaceutically acceptable salt, or N-oxide thereof, wherein



X is CR¹ or N;

X¹, X² and X³ are independently selected from -CR^z, -CR^z=CR^z, -CR^z=N, -N=CR^z, -N=N-, O-, -S- or -N-;

Z is selected from CR^c, S, O, NR^c, R^cC=CR^c, -N=CR^c-, and -R^cC=N-;

Z₁ is selected from N, NR^c and CR^c;

Z₂ and Z₃ are independently selected from C or N;

E is selected from -CONH-O-(CR^xR^y)_p-OR^x, -CONH-O-[cycloalkyl]-(CR^xR^y)_p-OR^x, and -CONH-O-(CR^xR^y)_p-[cycloalkyl]-OR^x and further D can optionally be substituted with one or more of R^z;

each occurrence of R¹ and R² hydrogen;

each occurrence of R^a and R^b may be same or different and are independently selected from hydrogen, halogen, and substituted or unsubstituted C₁₋₆ alkyl,

each occurrence of R^x and R^y is independently selected from hydrogen, hydroxy, substituted or unsubstituted alkyl, and substituted or unsubstituted alkoxy

each occurrence of R^z is independently hydrogen, halogen, or substituted or unsubstituted alkyl


each occurrence of q independently represents 0, 1 or 2;


each occurrence of p independently represents 1, 2, 3, 4, 5, 6, 7 or 8.


11. A compound of claim 2 or claim 10, wherein X^1 and X^2 are CR^z and X^3 is independently selected from $-CR^z=CR^z$ and $-S-$.

12. A compound of claim 11, wherein X^1 is CH, X^2 is CR^z and X^3 is $-CR^z=CR^z$, wherein R^z is hydrogen, halogen or substituted or unsubstituted C_{1-3} alkyl.


13. A compound of any one of claims 1-12, wherein D is selected from









14. A compound of claim 13, wherein D is selected from




15. A compound of any one of claims 1-12, wherein D is selected from



16. A compound of claim 15, wherein E is selected from



17. A compound of claim 15 or claim 16, wherein E is selected from



18. A compound of claim 15, wherein each occurrence of R^z is selected from hydrogen, halogen or substituted or unsubstituted alkyl.

19. A compound of claim 18, wherein each occurrence of R^z is selected from hydrogen, fluoro, chloro, methyl or CF_3 .

20. A compound of claims 9-19, wherein each of R^a and R^b is hydrogen, alkyl or halogen.

21. A compound of any one of claims 9-20, wherein

a) both R^a and R^b are hydrogen;

- b) R^a is methyl and R^b is hydrogen;
 - c) R^a is fluoro and R^b is hydrogen;
 - d) R^a and R^b both are fluoro; or
 - e) R^a and R^b both are methyl.
22. A compound of any one of claims 9-21, wherein
- Z is CR^c , N, S, O, $HC=CH-$ or $-N=CH-$;
- Z_1 is CH or N;
- Z_2 is C; and
- Z_3 is C or N.
23. A compound of any one of claims 9-22, wherein
- a) Z is $-HC=CH-$, $-S-$ or $-O-$; Z_1 is CH; Z_2 is C and Z_3 is C or N;
 - b) Z is $-HC=CH-$, Z_1 is CH; Z_2 is C; and Z_3 is C;
 - c) Z is CH, Z_1 is CH, Z_2 is C and Z_3 is N;
 - d) Z is $-S-$, Z_1 is CH, Z_2 is C and Z_3 is C;
 - e) Z is $-O-$, Z_1 is CH, Z_2 is C and Z_3 is C; or
 - f) Z is $-CH-$, Z_1 is NH, Z_2 is C and Z_3 is C.
24. A compound of any one of claims 9-23, wherein each occurrence of R^c is hydrogen or fluoro.
25. A compound of any one of claims 1-24, wherein X is N or CR^1 and R^1 is H, substituted or unsubstituted C_{1-6} alkyl, NH_2 , OH, CN or $CONH_2$.
26. A compound of any one of claims 1-25, wherein X is N.
27. A compound of any one of claims 1-26, wherein each R^2 is H.

28. A compound selected from:

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl) benzamide hydrochloride:

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 4-methylbenzenesulfonate

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrobromide:

sodium (2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide:

2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride:

sodium (2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2-chloro-4-(3-((7-fluoro-2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride:

sodium (2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide

2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride

sodium (2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2-fluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl acetate:

(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl 2-(tert-butoxycarbonylamino)propanoate:

(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl 2-aminopropanoate:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl pivalate:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl isobutyrate:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl 2-benzamidoacetate:

2-chloro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-chloro-N-(2-hydroxyethoxy)benzamide:

4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2,6-difluoro-N-(2-hydroxyethoxy)benzamide:

sodium (4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2,6-difluorobenzoyl)(2-hydroxyethoxy)amide:

4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-fluoro-N-(2-hydroxyethoxy)benzamide:

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride:

N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-(trifluoromethyl)benzamide:

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide:

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide hydrochloride:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrobromide:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 4-methylbenzenesulfonate:

N-(2-hydroxyethoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

6-((5-(4-(2-hydroxyethoxycarbonyl)-3-methylphenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline 1-oxide

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-methylbenzamide:

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-methylbenzamide hydrochloride:

2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide:

2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride:

2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

ethyl 2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)acetate:

2-chloro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

(S)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

(R)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2,6-difluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2-fluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

(S)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

(R)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

N-(1-hydroxy-2-methylpropan-2-yloxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

2-chloro-N-(1-hydroxy-2-methylpropan-2-yloxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-[3-(1-oxy-quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl]-benzamide

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl acetate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl isobutyrate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl pivalate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl benzoate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl furan-2-carboxylate

and pharmaceutically acceptable salts thereof.

29. A compound selected from:

N-(2-Hydroxy-ethoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide

N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide

2-Chloro-N-(2-hydroxy-ethoxy)-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide

2-Chloro-N-(2-hydroxy-2-methyl-propoxy)-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide:

or a pharmaceutically acceptable salt thereof.

30. A pharmaceutical composition comprising a compound of any one of claims 1-29 and a pharmaceutically acceptable carrier.
31. The pharmaceutical composition of claim 30, further comprising one or more additional therapeutic agents and mixtures thereof.
32. The pharmaceutical composition of claim 31, wherein the one or more additional therapeutic agent is an anti-cancer agent, anti-inflammatory agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, antihistamine, analgesic, or a mixture thereof.
33. Use of a compound of any one of claims 1-29 in the manufacture of a medicament for the treatment of a disease, disorder, or condition that would benefit from inhibiting catalytic activity of a kinase.
34. Use of a compound of claim 33, wherein the kinase is c-Met kinase.
35. A compound of any one of claims 1-29 for use in inhibiting the HGF/c-Met kinase signaling pathway in a cell.
36. A compound of any one of claims 1-29 for use in inhibiting the proliferative activity of a cell.
37. A compound of any one of claims 1-29 for use in inhibiting tumor growth.
38. A compound of any one of claims 1-29 for use in inhibiting tumor metastasis.

39. A compound of any one of claims 1-29 for use in the treatment of a c-Met associated disease or disorder.

40. A compound of any one of claims 1-29 for use in the treatment of a cancer.

41. The compound of claim 40, wherein said cancer is a carcinoma, musculoskeletal sarcoma, soft tissue sarcoma, or hematopoietic malignancy.

42. The compound of claim 41, wherein said cancer is carcinoma of the bladder, carcinoma of the breast, carcinoma of the colon, carcinoma of the kidney, carcinoma of the liver, carcinoma of the lung, small cell lung cancer, esophageal cancer, gall bladder cancer, ovarian cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, prostate cancer, skin cancer, squamous cell carcinoma; cholangiocarcinoma cancer, tumors of mesenchymal origin, fibrosarcoma, rhabdomyosarcoma; tumors of the central and peripheral nervous system, astrocytoma, neuroblastoma, glioma, schwannoma; melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderma pigmentosum, keratocanthoma, thyroid follicular cancer and Kaposi's sarcoma, synovial sarcoma, rhabdomyosarcoma, MFH/fibrosarcoma, leiomyosarcoma, multiple myeloma, lymphoma, glioblastoma, astrocytoma, melanoma, mesothelioma, Wilm's tumor, hematopoietic tumors of lymphoid lineage, leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, acute myelogenous leukemias, chronic myelogenous leukemias, myelodysplastic syndrome, or promyelocytic leukemia.